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Exosome-delivered microRNAs modulate the
inﬂammatory response to endotoxin
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MicroRNAs regulate gene expression posttranscriptionally and function within the cells in
which they are transcribed. However, recent evidence suggests that microRNAs can be
transferred between cells and mediate target gene repression. We ﬁnd that endogenous
miR-155 and miR-146a, two critical microRNAs that regulate inﬂammation, are released from
dendritic cells within exosomes and are subsequently taken up by recipient dendritic cells.
Following uptake, exogenous microRNAs mediate target gene repression and can repro-
gramme the cellular response to endotoxin, where exosome-delivered miR-155 enhances
while miR-146a reduces inﬂammatory gene expression. We also ﬁnd that miR-155 and
miR-146a are present in exosomes and pass between immune cells in vivo, as well as
demonstrate that exosomal miR-146a inhibits while miR-155 promotes endotoxin-induced
inﬂammation in mice. Together, our ﬁndings provide strong evidence that endogenous
microRNAs undergo a functional transfer between immune cells and constitute a mechanism
of regulating the inﬂammatory response.
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I
ntercellular communication is essential for immune cells to
coordinate inﬂammatory responses. Cytokines, chemokines
and cell surface receptors are well-known mediators of this
process. In addition to these classical signalling molecules,
emerging evidence suggests that immune cells can signal by
secreting small lipid packages called exosomes, which carry a
variety of different molecules that can be taken up by recipient
cells1–4. The functional relevance of exosomes in many different
biological systems, including the immune system, is beginning to
be demonstrated5–11.
MicroRNAs (miRNAs) are important modulators of gene
expression that function by targeting messenger RNAs for
degradation or preventing translation. Typically, miRNAs
are thought to function within the cells in which they are
made; however, recently, miRNAs have been observed in secreted
exosomes12–14. Immune cells, including antigen-presenting
dendritic cells (DCs) and T lymphocytes, can both secrete and
take up exosomal miRNAs, suggesting that exosomal transfer
of miRNAs could be a novel mechanism for intercellular
communication12,14,15. Furthermore, recent studies indicate
that the loading of miRNAs into exosomes is a selective process
where speciﬁc motifs in miRNA sequences are recognized
by the RNA-binding protein, hnRNPA2B1 (ref. 16). Other
reports ﬁnd that miRNA loading into exosomes is dependent
on 30-end uridylated isoforms17 and on the levels of miRNA
targets in producer cells18. Consistent with this, exosomal
miRNA signatures do not simply reﬂect the miRNA
composition of the parent cell, but are composed of a distinct
set of miRNAs16,18–21. This argues that certain miRNAs have
evolved to be packaged into exosomes to carry out their biological
functions.
Exosomally transferred miRNAs are emerging as novel
regulators of cellular function. There is evidence in both immune
cells and other cell types that transferred miRNAs repress target
mRNAs in recipient cells12–14,22–24. The transfer of miRNAs can
also cause physiological changes in recipient cells5–7, as
demonstrated by miRNAs moving from cancer cells to
endothelial cells, which promotes tumour metastasis5. Cancer
cells can also receive exosomal miRNAs secreted from immune
cells, which were shown to have an anti-proliferative effect on the
tumour cells7. These data suggest that different cell types can
secrete or receive miRNAs as a form of communication and have
set the stage for investigating the functional roles of transferred
miRNAs in the context of immune responses.
Within the immune system, several speciﬁc miRNAs have
recently emerged as important regulators of immune cell function.
Among these, miR-155 is a promoter of inﬂammatory responses,
while miR-146a is a mediator of immune suppression25–28.
Despite signiﬁcant progress in our understanding of how these
miRNAs inﬂuence immunity in vivo, there are many aspects
of their regulation and function that remain unclear. In the
current study, we investigate whether endogenous miR-155 and
miR-146a are functionally transferred between primary bone
marrow-derived DCs (BMDCs). We ﬁnd that both of these
miRNAs are released within exosomes and are taken up by
recipient BMDCs. On uptake, the miRNAs are associated with
Ago proteins, knock down their respective targets and
reprogramme the response of BMDCs to endotoxin challenge.
We also show that miR-155 can be transferred between immune
cells in vivo. Finally, we demonstrate that injection of miR-146a-
containing exosomes into mice inhibits their inﬂammatory
response to endotoxin, whereas injection of miR-155-containing
exosomes promotes inﬂammation following exposure to the
same inﬂammatory stimulus. Our study supports a model
whereby exosomal miRNAs participate in the regulation of
inﬂammatory responses.
Results
miR-155 is found in exosomes and transferred between BMDCs.
miR-155 is an immunomodulatory miRNA expressed by many
types of immune cells including DCs27. We sought to determine
whether miR-155 could be passed between cultured BMDCs. Co-
cultures of primary mouse BMDCs derived from CD45.1þ Wt
mice and CD45.2þ miR-155 / mice were set up at a 1:1 ratio
with and without lipopolysaccharide (LPS) treatment (Fig. 1a). As
a control, miR-155 / BMDCs were also cultured under the
same conditions without Wt cells. After 24 h, the co-cultured Wt
and miR-155 / CD11cþ BMDCs were separated based on
their differential CD45 markers using ﬂuorescence-activated cell
sorting (FACS) (Fig. 1b). Quantitative reversetranscriptase–PCR
(qRT–PCR) was performed on RNA isolated from the CD45.2þ
miR-155 / BMDCs. miR-155 was detected in miR-155 /
BMDCs that were cultured withWt cells and the signal was clearly
above background levels established using miR-155 / BMDCs
cultured alone (Fig. 1c). When cells were treated with LPS, the
transfer of miR-155 to miR155 / cells was increased,
consistent with previous ﬁndings that cellular miR-155
concentrations are elevated following LPS stimulation29 (Fig. 1c).
To determine whether cell–cell contact is necessary for the
transfer of miR-155, we used 0.4-mm ﬁlters to separate
miR-155 / and Wt BMDCs that were co-cultured in the
presence or the absence of LPS for 24 h. The 0.4-mm pore size
allows for small molecules and vesicles such as exosomes to pass
through but prevents cell-contact-mediated exchange of mate-
rial23. We detected miR-155 in the miR-155 / BMDCs that
were cultured with Wt BMDCs, which was above background
(Fig. 1d). Our data indicate that miR-155 is passed between cells,
and that cell–cell contact is not necessary for transfer to occur
between BMDCs.
As miRNAs have recently been shown to be transferred
between immune cells within exosomes, we investigated whether
miR-155 is contained within these secreted vesicles. To address
this question, we isolated the exosomal pellet from Wt or
miR-155 / BMDC conditioned media using differential
centrifugation. Both electron microscopy (EM) and a CD63
western blotting of the isolated vesicles indicated that we had
successfully isolated exosomes (Fig. 1e,f). Using qRT–PCR, we
found that miR-155 was contained in exosomes derived from Wt
BMDCs but not in exosomes derived from miR-155 / cells
(Fig. 1g). BMDCs treated with LPS enhanced the levels of miR-
155 found in the exosomal pellet, consistent with higher levels of
miR-155 being produced by the activated BMDCs. In addition,
we blocked exosome formation by treating donor BMDCs with
GW4869, a drug that hinders exosome biogenesis by blocking
neutral sphingomyelinase 2 (nSMase2) (refs 13,15). Following
drug treatment, the pellet contained signiﬁcantly reduced
exosomes as determined by EXOCET quantiﬁcation (Fig. 1h),
CD63 western blotting and EM (Supplementary Fig. 1). Drug
treatment also prevented the detection of miR-155 in the
exosomal pellet (Fig. 1i), suggesting that miR-155 is contained
within exosomes. In addition, we derived BMDCs from Rab27a
and Rab27b double-knockout mice (Rab27 DKO), which have
been previously shown to have decreased release of exosomes23.
We found that Rab27 DKO BMDCs had both decreased exosome
release (Fig. 1j) and a corresponding decrease in miR-155 in the
exosomal pellet (Fig. 1k). Together, these data show that miR-155
can be passed between BMDCs, and that miR-155 is contained in
exosomes produced by BMDCs.
Exosomal transfer of miR-155 is functionally relevant. With the
knowledge that miR-155 can be transferred between BMDCs, we
wanted to determine whether exosomes are sufﬁcient for this
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transfer and whether transfer could result in knockdown of
target mRNAs. To speciﬁcally investigate the impact of exo-
somally transferred miRNA without the effects of other factors
that are released from BMDCs, we puriﬁed exosomes away
from other components in the conditioned medium using
differential centrifugation and washing. Next, the exosomes were
re-suspended in fresh medium and administered to recipient
cells.Wt (1 106) or miR-155 / BMDCs producedB5 108
exosomes in 24 h (Supplementary Fig. 2). Exosomes isolated from
the supernatant of both Wt and miR-155 / BMDCs treated
± LPS
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Figure 1 | miR-155 is transferred between BMDCs and is present in exosomes. (a) A schematic of the co-culture experiment. (b) Representative FACS
plots where co-cultured CD45.1þ Wt and CD45.2þ miR-155 / CD11cþ BMDCs were separated (n¼4). (c) Relative miR-155 levels were quantiﬁed via
qRT–PCR from isolated miR-155 / BMDCs that had been cultured alone or with Wt BMDCs in the presence or the absence of LPS for 24 h (n¼4).
(d) Relative miR-155 levels were measured via qRT–PCR in miR-155 / BMDCs either cultured alone or with Wt BMDCs separated by a 0.4-mm ﬁlter for
24 h with or without LPS (n¼ 3). (e) Cryo-EM of exosomes isolated from Wt BMDCs. Scale bar, 200nm. Red box is enlarged in the upper left corner.
(f) CD63 protein levels in the exosomal pellet from Wt and miR-155 / BMDCs treated with or without LPS. (g) Relative levels of miR-155 in exosomes
derived fromWt or miR-155 / BMDCs treated with or without LPS (n¼ 3). (h) Exosome quantiﬁcation ofWt BMDCs treated with or without GW4869
(n¼ 3). Limit of detection is 2 107 exosomes. (i) Relative levels of miR-155 were measured in the exosomal pellet from Wt BMDCs treated with or
without LPS and GW4869 as quantiﬁed by qRT–PCR (n¼ 2). (j) Exosome quantiﬁcation of Wt and Rab27 DKO BMDC-derived exosomes (n¼ 2). Limit of
detection is 2 107 exosomes. (k) miR-155 levels in exosome pellets from Wt and Rab27 DKO BMDC-conditioned medium (n¼ 2). Data represent two
independent experiments and are presented as the mean±s.d. (error bars). *Po0.05; **Po0.01, Student’s t-test.
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with GW4869 or dimethylsulfoxide vehicle control were trans-
ferred to miR-155 / receipient BMDCs. miR-155 /
recipient BMDCs were incubated with donor exosomes for 24 h,
to allow time for miRNA transfer and knockdown of miRNA
targets (Fig. 2a). Using qRT–PCR, we detected increased miR-155
levels and decreased mRNA levels of miR-155 targets BACH1
and SHIP1 when cells were treated withWt exosomes (Fig. 2b–d).
These changes were prevented if the exosomes were derived from
miR-155 / BMDCs, or if the Wt donor cells were pretreated
with GW4869. SHIP1 protein levels were also decreased in
miR-155 / BMDCs that received Wt exosomes (Fig. 2e,f).
Exosome delivery of miR-155 brought its levels in the
WT
WT
*
*
*
0.1429
*
0
1
2
3 1.5
1.0
0.5
0.0R
el
at
ive
 
m
iR
-1
55
 le
ve
ls
R
el
at
ive
 m
iR
-1
55
 le
ve
ls
m
iR
-1
55
 le
ve
ls
(A
go
/Ig
G)
m
iR
-1
46
a 
le
ve
ls
(A
go
/Ig
G)
R
el
at
ive
 S
HI
P1
 le
ve
ls
R
el
at
ive
 S
HI
P1
le
ve
ls
R
el
at
ive
 B
AC
H1
 le
ve
ls
R
el
at
ive
 S
HI
P1
pr
ot
ei
n 
le
ve
ls
R
el
at
ive
 H
O
1 
lev
e
ls
R
el
at
ive
 B
AC
H1
 le
ve
ls
Exosome
donor
Exosome
donor
SHIP1
β-Actin
Recipient
cell
GW4869
WT
– –+ +
155–/–
155–/– 155–/–
155–/–155–/–155–/–155–/–
WTExosomedonor
Recipient
cell
GW4869
WT
+WT +155–/–
155–/– recipient cells
– –+ +
155–/– 155–/–
155–/–155–/–155–/–155–/–
25 2.5
2.0
1.5
0.0651
0.0662
0.0600
0.07758
6
4
2
0
1.0
0.5
0.0
20
15
10
5
0
*
WT
WT
Exosome
donor
Exosome
donor
Recipient
cell
Recipient
cell
GW4869
WT
– –+ +
155–/– 155–/–
155–/–155–/–155–/–
155–/– 155–/–
155–/–
WT
WT WT
Exosome
donor
0
1
2
3 *
Recipient
cell
155–/–WT
WT WT
Exosome
donor
Recipient
cell
155–/–WT
WT WT
Exosome
donor
Recipient
cell
155–/–
WT
WT WT WT
WT WTWTExosomedonor
Exosome
donor
Recipient
cell
Recipient
cell
Input
0 0
10
2 2
4
4
6
6
8
8
Input
Ago2
β-Actin
Exosome
donor
AGO IP IgG IP
Input αAgo αAgo Input Input αAgo αAgo
155–/–
155–/–155–/–155–/–
155–/– recipient cells
155–/– 155–/–
155–/–
155–/– 155–/–
155–/–155–/–
155–/– 155–/– 155–/–
155–/–
155–/–
1.5
1.0
0.5
0.0
WT
Exosome
donor
Recipient
cell
GW4869
WT
– –+ +
155–/– 155–/–
155–/–155–/–155–/–155–/–
± GW4869
Isolate exosomes via
differential centrifugation
Recipient 155–/– BMDCs
2.0
*
*
**
1.5
1.0
0.5
0.0
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8321
4 NATURE COMMUNICATIONS | 6:7321 | DOI: 10.1038/ncomms8321 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
miR-155 / recipient cells to B20% of Wt miR-155 levels
(Supplementary Fig. 3a,b). Furthermore, we also looked at the
relative expression of a separate miRNA, miR-425, which has
been previously seen to be released in exosomes30, as a control.
The levels of miR-425 increased with exosome delivery and were
roughly the same in Wt and knockout groups (Supplementary
Fig. 3c,d).
In addition to using miR-155 / recipient cells, which
provide a clean background to clearly detect the transferred
miRNA, we also examined whether transferred miR-155 could be
detected in Wt BMDC recipients. miR-155 levels were increased
on treatment of Wt BMDCs with Wt exosomes but were not
increased when treated with miR-155 / exosomes (Fig. 2g).
In addition, the mRNA levels of both BACH1 and SHIP1 were
decreased in Wt BMDCs receiving exosomal miR-155 (Fig. 2h,i).
These data indicate that miR-155 can be transferred between Wt
BMDCs in exosomes, resulting in the knockdown of known miR-
155 targets.
As we have found that miR-155 can knock down its targets in
recipient cells, we next investigated whether the transfer of miR-
155 alters downstream factors in recipient cells. We found that
exosomal miR-155 increased the expression of HO1 (Fig. 2j), an
oxidative stress response gene that is well known to be repressed
by BACH1, a gene we have shown is targeted by transferred miR-
155 (ref. 29; Fig. 2c). These results indicate that transferred miR-
155 not only represses its putative direct targets but can also affect
factors that are downstream of these targets.
To further characterize the functional transfer of miR-155
between BMDCs, we examined whether transferred miR-155 is
associated with AGO proteins that are essential for miRNA-
mediated knockdown of targets. Following exosomal transfer of
miR-155 into miR-155 / BMDCs, an AGO immunoprecipi-
tation (IP) was performed using a pan-AGO antibody and
western blotting for AGO2 was preformed to verify pulldown was
occurring. Using qRT–PCR, we found that miR-155 is associated
with AGO proteins in miR-155 / recipient cells (Fig. 2k,l).
We did not detect miR-155-associated AGO proteins when miR-
155 / BMDCs were treated with miR-155 / exosomes.
Further, AGO2 was not detected via western blotting and miR-
155 was not pulled down when an isotype control antibody was
used. As an additional control, we found that another miRNA,
miR-146a, was also enriched in the AGO pulldown from both
groups (Fig. 2m). These data demonstrate that exosomal miR-155
is associated with AGO proteins, key components of the RNA-
induced silencing complex (RISC) complex, following its uptake
by recipient BMDCs.
Exosomal transfer of miR-146a is functionally relevant.
miR-146a is an important anti-inﬂammatory miRNA involved in
DC function27 and plays an opposing role to miR-155 during
inﬂammatory responses25,31. We wanted to determine whether
miR-146a was also contained in BMDC-derived exosomes; hence,
we isolated exosomes from Wt BMDCs that had been treated with
or without GW4869 and/or LPS, and found that miR-146a was
contained in exosomes from untreated BMDCs but was not
present in the exosomal pellet from BMDCs treated with GW4869
(Fig. 3a). miR-146a is marginally increased in exosomes from
BMDCs treated with LPS. In addition, reductions in miR-146a
were observed in the extracellular exosomal fraction obtained from
Rab27 DKO BMDCs compared with Wt controls (Fig. 3b). These
data reveal that miR-146a is contained within exosomes released
from BMDCs.
To test whether miR-146a could be functionally transferred
between BMDCs, we isolated exosomes fromWt ormiR-146a /
BMDCs and administered them to miR-146a / BMDCs
(Fig. 3c). Similar to miR-155, we observed that exosomal
miR-146a was taken up by recipient BMDCs (Fig. 3d), and that
miR-146a targets, IRAK1 and TRAF6, were repressed in recipient
BMDCs receiving Wt but not miR-146a / exosomes looking at
both the mRNA and protein levels (Fig. 3e–j). In addition, we
calculated miR-146a copy number in Wt and miR-146a /
exosomes where we found approximately one copy of miR-146a per
exosome (Fig. 3k). miR-146a copy number was also calculated inWt
and miR-146a / donor BMDCs and BMDCs that received
either Wt or miR-146a / exosomes (Fig. 3l). We observed an
average of 370 copies present in recipient BMDCs following
exosomes treatment. It has been suggested that 100–1,000 copies of
miRNA per cell is likely to be functionally relevant32. As a control,
we investigated the relative expression of miR-425, which was
similar between the genotypes (Supplementary Fig. 3e,f). Our copy
number data along with our observations of target knockdown are
consistent with exosomally transferred miR-146a having functional
relevance.
Recently, it has been shown in human B-cell lines that miRNAs
are selectively packaged into exosomes based on 30-non-
templated nucleotide additions (NTAs)17 where 30-uridylation
was enriched in miRNAs contained in exosomes and
30-adenylation was enriched in miRNAs retained in cells. To
address whether we observe a similar phenomenon, RNA
sequencing was performed using RNA from Wt donor BMDCs
and miR-155 and miR-146a DKO BMDCs that had received
Wt exosomes. Next, we used a previously reported approach to
identify NTAs in our data set17. However, we did not observe an
enrichment of 30-uridylation in transferred miR-155 or miR-146a
(Supplementary Fig. 4). This difference from previous ﬁndings
could be due to species and cellular differences (mouse primary
BMDCs versus human B-cell lines) or further processing of the
transferred miRNAs in recipient cells. However, we did observe
some differences at certain nucleotide positions in each respective
mature miRNA sequence when comparing Wt donor BMDCs
with DKO BMDCs that received Wt exosomes (Supplementary
Tables 1 and 2). These results are consistent with the idea that
alterations to the mature miRNA sequence may inﬂuence miRNA
loading into exosomes versus cellular retention.
Figure 2 | Functional transfer of miR-155 via exosomes in vitro. (a) Schematic of the exosome transfer experiment. (b) qRT–PCR was used to
measure relative miR-155 levels in miR-155 / BMDCs that received eitherWt or miR-155 / exosomes derived from BMDCs treated with or without
GW4869 (n¼ 5). (c,d) mRNA levels of miR-155 targets, BACH1 and SHIP1, from the same experiment shown in b as measured by qRT–PCR (n¼ 5).
(e) Representative western blottings of SHIP1 and b-actin in miR-155 / BMDCs given either Wt or miR-155 / exosomes. (f) Protein levels of SHIP1
were quantiﬁed using ImageJ software (n¼ 2). (g) Relative miR-155 levels in Wt BMDCs given either Wt or miR-155 / exosomes as quantiﬁed by
qRT–PCR (n¼6). (h,i) BACH1 and SHIP1 mRNA levels were measured in the same experiment shown in g as quantiﬁed by qRT–PCR (n¼6). (j) qRT–PCR
was used to quantify HO1 mRNA levels during the experiment in b (n¼ 5). (k) Western blotting for AGO2 and b-actin from miR-155 / BMDCs given
Wt or miR-155 / exosomes. On the left is the input (whole-cell lysate), the middle is from the pan-AGO pulldown where one-third of input was used
and the right is the IgG pulldown where one-third of the input was used. (l) Relative miR-155 levels were quantiﬁed via qRT–PCR in the same experiment
shown in k. (m) miR-146a levels were quantiﬁed using qRT–PCR during the experiment in k. Levels in l,m are plotted as Ago:IgG. Dotted line separates
input from pull-down groups. Data represent two independent experiments and are presented as the mean±s.d. (error bars). *Po0.05; **Po0.01,
Student’s t-test.
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Figure 3 | Functional transfer of miR-146a via exosomes in vitro. (a) Levels of miR-146a in the exosomal pellet derived from BMDCs that were treated
with or without GW4869 and LPS (n¼ 2). (b) miR-146a levels in Wt and Rab27 DKO BMDC-derived exosomal pellets (n¼ 2). (c) Schematic of miR-146a
exosome-transfer experiment where Wt or miR-146a / exosomes were isolated from BMDCs and transferred to recipient miR-146a / BMDCs.
RNA was isolated after 24 h and the presence of miR-146a was assayed via qRT–PCR. (d) Relative levels of miR-146a in miR-146a / BMDCs given
exosomes derived from Wt or miR-146a / BMDCs (n¼4). (e) mRNA levels of miR-146a target, IRAK1, were measured from the same cells as in d via
qRT–PCR (n¼4). (f) Representative western blottings of IRAK1 and b-actin from miR-146a / cells given either Wt or miR-146a / exosomes.
(g) IRAK1 protein levels were quantiﬁed using ImageJ software (n¼ 2). (h) mRNA levels of miR-146a target, TRAF6, were measured in the same cells as in
d via qRT–PCR. (i) Western blottings for TRAF6 and b-actin from miR-146a / BMDCs given either Wt or miR-146a / exosomes (n¼ 2).
(j) Western blotting results are quantiﬁed with ImageJ software. (k) Copy number of miR-146a in Wt and miR-146a / exosomes (n¼ 3). Copy number
is calculated based on a standard curve where a known amount of synthetic miR-146a was spiked into miR-146a / BMDC-derived exosome pellet
followed by RNA isolation and qRT–PCR. (l) Copy number of miR-146a was measured via qRT–PCR in miR-146a / recipient BMDCs that received either
Wt or miR-146a / exosomes (146a / BMDCþWt exos and 146a / BMDCþ 146a / exos), as well as in Wt and miR-146a / donor
BMDCs (n¼ 3). Average copy number is displayed above. Copy number is calculated based on a standard curve where a known amount of synthetic
miR-146a was spiked into miR-146a / BMDC pellet followed by RNA isolation and qRT–PCR. Data represent two independent experiments and are
presented as the mean±s.d. (error bars). *Po0.05, Student’s t-test.
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Seed-dependent repression of miRNA targets. We next deter-
mined whether miR-155 and miR-146a mimic-loaded exosomes
were sufﬁcient to mediate direct target knockdown in recipient
cells. miR-155 / or miR-146a / BMDCs were transfected
with either corresponding miRNA mimics, scrambled miRNA
mimics, or seed mutant miRNA mimics for 24 h, then washed
three times with PBS to remove any mimics that did not make it
into the cells (Fig. 4a). We isolated exosomes from the cells after
24 h and transferred them to recipient knockout BMDCs. After
24 h, RNA was isolated from the cells and qRT–PCR was per-
formed to assay the delivery of mimics and the knockdown of
target mRNAs. We found that miRNA mimics could be suc-
cessfully loaded into exosomes and delivered to recipient cells
(Supplementary Figs 5 and 6). The transfer of miRNA mimics
containing exosomes resulted in knockdown of respective target
mRNAs in recipient BMDCs (Fig. 4b–f). However, exosomes that
did not carry mimics, or that carried scrambled or seed mutant
mimics, caused no change in target mRNA expression in reci-
pient cells. These results indicate that exosomal miRNAs are
responsible for direct target repression and are able to comple-
ment the target knockdown phenotype.
To further assess whether exosomal miRNA target repression
was direct, we used 30-untranslated region (UTR) luciferase reporter
assays. Knockout BMDCs were transfected with 30-UTR luciferase
reporters for 6 h followed by treatment with or without Wt
exosomes (Fig. 4g). miR-155 / BMDCs were transfected with
either a pmiReport empty vector control, BACH1 30-UTR, BACH1
miR-155-binding site (bs) mutant 30-UTR, or a miR-155-positive
control (2mer). Luciferase activity in cells receiving the BACH1
30-UTR or 2mer reporter constructs was reduced in response to
miRNAs delivered by exosomes, while the exosomal miRNAs had
little impact on luciferase activity in cells receiving the pmiReport
empty vector or the BACH1 miR-155 bs mutant 30-UTR reporter
(Fig. 4h). In a separate experiment, miR-146a / BMDCs
were transfected with either a pmiReport empty vector control,
TRAF6 30-UTR, or a TRAF6 miR-146a bs mutant 30-UTR. The
BMDCs transfected with the TRAF6 30-UTR had decreased
luciferase activity compared with the pmiReport empty vector
and the TRAF6 miR-146a bs mutant 30-UTR following exosome
delivery of miRNAs (Fig. 4i). These results indicate that exosomally
transferred miRNAs directly repress their targets via direct 30-UTR
interactions.
Exosomal miR-155 and miR-146a modulate the response to LPS.
To determine whether the transfer of miR-155 via exosomes could
affect the BMDC response to LPS, exosomes were isolated fromWt
or miR-155 / BMDCs and transferred to miR-155 /
BMDCs. Twenty-four hours later, cells were treated with LPS for
6 h (Fig. 5a). Consistent with a previously reported role for miR-
155 in promoting interleukin (IL)-6 expression33 and previously
reported roles of miR-155-regulated responses to endotoxin34, cells
that were treated with miR-155-containing exosomes produced
more IL-6 on treatment with LPS for 6 h than cells having received
miR-155 / exosomes (Fig. 5b). These ﬁndings indicate that
exosomes containing miR-155 can reprogramme recipient BMDCs
in a manner that enhances their response to LPS.
miR-146a is known to induce an anti-inﬂammatory response
to LPS26. Therefore, we wanted to investigate whether exosomally
transferred miR-146a can programme BMDCs to respond in an
anti-inﬂammatory manner, using a similar experimental setup as
we did for miR-155 (Fig. 5c). BMDCs pre-treated with Wt
exosomes produced more IL-10, but less IL-6 and IL-12 p40,
following LPS stimulation than BMDCs that received
miR-146a / exosomes (Fig. 5d–f). This gene expression
proﬁle demonstrates that miR-146a-containing exosomes reduce
the pro-inﬂammatory response by BMDCs following LPS
treatment. Without LPS treatment, there was no signiﬁcant
difference in IL-10, IL-6 or IL-12 p40 expression by cells receiving
Wt versus miR-146a / exosomes (Fig. 5d–f), indicating that
exosomal miR-146a speciﬁcally alters how these cells respond to
LPS. Similar to miR-155, our data indicate that miR-146a is
functionally transferred in exosomes and able to cause
physiological changes in recipient cells. However, unlike miR-
155, exosomal miR-146a acts to dampen the inﬂammatory
response to LPS. These results are consistent with previous
observations that miR-155 and miR-146a play opposing roles
during inﬂammation25,31.
miR-155 is transferred between immune cells in vivo. As we
observed functional transfer of miRNAs in vitro, we wanted to
determine whether miRNAs could be transferred between
immune cells in vivo. We ﬁrst investigated whether exosomes
were present in mouse BM by isolating exosomes directly from
the BM of Wt and miR-155 / mice using differential cen-
trifugation. We found that both genotypes had exosomes present
in the BM (Fig. 6a), and that miR-155 was expressed in Wt BM
exosomes (Fig. 6b), whereas miR-146a was present in exosomes
from both genotypes (Fig. 6c). We next determined whether miR-
155 was passed between immune cells in vivo. To investigate this,
miR-155 / mice were lethally irradiated and reconstituted
with either an equal mix of CD45.1þ Wt and CD45.2þ miR-
155 / BM or just miR-155 / BM. After allowing 3
months for reconstitution, we injected mice with LPS to stimulate
production of miR-155 by BM cells (Fig. 6d). BM cells were
isolated 24 h after LPS stimulation and miR-155 / haemato-
poietic cells were sorted via FACS according to their different
CD45 alleles (Fig. 6f). We also further fractionated the miR-
155 / BM into B-cell, myeloid cell and T-cell fractions using
the surface markers B220, CD11b and CD3, respectively
(Fig. 6g,h). Using qRT–PCR, we detected miR-155 expression in
miR-155 / B cells, T cells and myeloid cells taken from miR-
155 / mice that had been reconstituted with both Wt and
miR-155 / BM (Fig. 6e). As a control, no miR-155 expression
was observed in cells from mice reconstituted with only miR-
155 / BM. These data provide evidence that miR-155 is
located within exosomes within the BM and is transferred
between immune cells in vivo.
To determine whether miRNA-containing exosomes could
deliver miRNAs to various cell types in vivo, we intraperitoneally
(i.p.) injected B109 exosomes derived from miR-155 / or
Wt BMDCs into miR-155 / mice. After multiple injections
over a week, the spleens of these mice were harvested and CD3þ
T cells, B220þ B cells and CD11bþ myeloid cells were sorted via
FACS. We found that miR-155 was delivered to all three of these
cell types in the spleen (Fig. 6i–k). This indicates that exosomes
are able to deliver miRNAs to various immune cell types.
Exosomal miR-155 enhances inﬂammatory responses in vivo.
Our in vitro data suggest that exosomally delivered miR-155 can
increase the BMDC response to LPS (Fig. 5b). Owing to these
observations, we investigated whether we could see the same
effect in vivo. Approximately 109 Wt or miR-155 / BMDC-
derived exosomes were i.p. injected into miR-155 / mice,
followed by administration of LPS 24 h later and collection of
serum 2 h after that (Fig. 7a). The injection of Wt exosomes
before LPS administration resulted in increased tumour necrosis
factor-a (TNFa) and trending elevations in IL-6 serum con-
centrations compared with mice pretreated with miR-155 /
exosomes (Fig. 7b,c). In addition, we observed that miR-155 was
delivered to the spleen, liver and BM, where we also found
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reduced target mRNA levels consistent with miR-155 activity in
these tissues (Fig. 7d–i). These data demonstrate that miR-155
can be functionally delivered to a variety of tissues and cell types
via exosome injection, and that this can increase the response to
LPS in vivo.
Exosomal miR-146a reduces inﬂammatory responses in vivo.
We next investigated whether exosomes containing miR-146a
would have an anti-inﬂammatory impact following LPS admin-
istration to mice. Approximately 109 exosomes were isolated
from Wt or miR-146a / BMDCs and injected i.p. into
miR-146a / mice. Twenty-four hours later, the mice were
given LPS and serum was collected after 2 h to assay inﬂamma-
tory cytokine levels (Fig. 8a). Mice having received Wt,
miR-146a-containing exosomes had reduced TNFa and IL-6
serum concentrations after LPS administration compared with
mice having received miR-146a-deﬁcient exosomes (Fig. 8b,c).
Exosomes alone had a negligible effect on cytokine levels in vivo.
Further, 24 h after LPS injection we isolated the spleen, liver and
BM, and found that miR-146a was clearly present in these tissues
from mice receiving Wt exosomes but was not present in tissues
from mice that received miR-146a / exosomes (Fig. 8d–f). In
addition, miR-146a targets involved in Toll-like receptor (TLR)
signalling were repressed in tissues in mice that received Wt
exosomes (Fig. 8g–i). Similar results were obtained when miR-
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146a-containing exosomes were administered to Wt recipients
(Fig. 9a–i). Together, these data demonstrate that exosomal miR-
146a can reduce the inﬂammatory response to LPS in mice.
Discussion
Although exosomes have been studied for a number of years, the
biological roles of exosomal miRNAs are just beginning to be
investigated4–8. Our data demonstrate that miRNAs 155 and 146a
are released from BMDCs in exosomes, are taken up by recipient
BMDCs and subsequently mediate target gene repression. In
addition, we have found that the transfer of miR-155 or miR-146a
can alter the ability of recipient cells to respond to inﬂammatory
cues both in vitro and in vivo. The capacity of these transferred
miRNAs to inﬂuence the response of BMDCs to a pro-
inﬂammatory stimulus suggests that the transfer of miRNAs is
an important mechanism by which immune cells are primed to
respond to an imminent encounter with a microbe. As miR-155
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and miR-146a have been shown to regulate inﬂammation in a
variety of contexts, our ﬁndings provide novel insights into how
and where they function, providing a greater understanding of
how they regulate mammalian immunity. Furthermore, our study
adds to the growing body of evidence that miRNA transfer within
exosomes is part of the intercellular communication networks
that coordinates complex immune responses8,12,14.
Previous studies have used cell lines, miRNA overexpression
and/or miRNA reporter constructs to study exosomal transfer
of miRNAs12–14. Although these approaches have provided
important evidence that miRNAs can be transferred in
exosomes, we designed our approach to be as physiologically
relevant as possible. miRNAs were produced at endogenous levels
by primary cells and established endogenous miRNA target genes
were used as readouts for miRNA activity in recipient cells.
Furthermore, exosomes were puriﬁed away from other BMDC
factors, such as cytokines, and miR-155- and miR-146a-deﬁcient
recipient cells were used to conﬁdently track the delivery and
speciﬁc effects of the exosomally delivered miRNA both in vitro
and in vivo.
A recent report has claimed that the amounts of speciﬁc
miRNAs contained within exosomes is less than one copy per
exosome35. Our copy number analysis found there to be
approximately one copy of miR-146a per exosome, consistent
with exosomes having low content of individual miRNAs.
However, we found that one BMDC produces B500 exosomes
after 24 h of culture, indicating that each cell is able to release at
least hundreds of copies of miR-146a in exosomes to be delivered
to recipient BMDCs and mediate target knockdown. Thus, it
seems that the large numbers of exosomes produced per cell
allows for the loading of low miRNA numbers per exosome to
achieve functional relevance.
It is important to note that exosome populations produced by
Wt cells contain both miR-155 and miR-146a, which we show
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have either pro- or anti-inﬂammatory effects, respectively. There
are several possible reasons why exosome populations would
contain both of these functionally distinct miRNAs species. First,
exosomes could be transferring both pro- and anti-inﬂammatory
miRNAs together to buffer inﬂammatory responses by recipient
cells, to achieve the optimal magnitude of response. Second, it is
plausible that miR-155 and miR-146a are located in separate
exosomes that are delivered to different target cell types. A third
possibility is that miR-155 and miR-146a release in exosomes is a
dynamically regulated process where the ratio of miR-155 to miR-
146a changes over time. For example, immune cells that have
sensed a pathogen could initially release exosomes with high
levels of pro-inﬂammatory miRNAs such as miR-155 followed by
a shift to anti-inﬂammatory miRNAs such as miR-146a during
the resolution phase of the response. These possibilities will be
explored in future studies wherein the analysis of single exosomes
may be required.
Exosomes are clearly complex vesicles that contain an
assortment of different membrane and soluble proteins, as well
as different types of RNAs, including miRNAs3. Thus, we cannot
formally rule out that exosomes produced by Wt versus miR-
155 / or miR-146a / BMDCs may differ in some aspect
other than the presence or the absence of the corresponding
miRNA that has been genetically deleted, and that this may also
have some inﬂuence on the inﬂammatory response by recipient
cells. However, we have been able to address this possibility to
some degree by successfully complementing the exosomal
miRNA target gene phenotypes by loading miRNA mimics into
miRNA knockout exosomes. Further, we were also able to
demonstrate that target repression is direct through the use of
seed mutant mimics that failed to repress target gene expression
in recipient cells as well as 30-UTR luciferase reporter assays
where binding-site mutant 30-UTRs were not repressed by
exosomally transferred miRNAs. Collectively, these data
strongly support the idea that individual miRNAs in exosomes
are transferred between cells in a functionally relevant manner.
We also observed transfer of miRNAs between immune cells
in vivo, indicating that this mechanism of cellular communication
is also occurring in a physiologically relevant setting. Future work
will be needed to isolate and study distinct cell types in the
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context of exosome production and uptake, as tissues such as the
spleen, liver and BM are made up of a heterogeneous populations
of cells that probably differ in their capacity to participate in these
processes. Further, we predict that functional miRNA transfer via
exosomes will be most relevant in deﬁned microenvironments
such as stem cell niches or within tumours, where exosome
concentrations might be at their highest.
Future studies will also require reagents where the production
of miRNA-containing exosomes can be speciﬁcally blocked
in vivo to assess the relevance of this mechanism in distinct
inﬂammatory settings. Rab27 DKO mice will provide one such
reagent despite possible roles for Rab27 a and b in exosome-
independent cellular processes. However, it is unclear whether the
release of pro- or anti-inﬂammatory exosomal miRNAs will have
a dominant impact on the inﬂammatory response in vivo, and we
predict that this will probably be context dependent. However, as
Rab27 DKO regulatory T cells have recently been shown to be
functionally impaired, it is likely to be that these animals will have
heightened inﬂammatory responses23. Consequently, the
relevance of exosomal miRNA release by distinct immune cell
types may have to be studied using cell-type-speciﬁc Rab27 DKO
mice.
Exosomal miRNAs are currently being extensively studied as
biomarkers of disease, as their serum levels are altered in a variety
of pathological conditions36–38. Our results, in combination with
others, suggest that these differences have functional consequences.
As exosomes appear to be a natural way that cells transfer
miRNAs, there is also growing interest in understanding the
therapeutic potential of exosomes as delivery vehicles for speciﬁc
miRNAs or their inhibitors39–44. Producing exosomes from
patients’ own cells may serve as an ideal vehicle for autologous
therapies involving miRNA delivery, and our capacity to load
miRNA mimics suggests that the miRNA content of exosomes can
be manipulated. Further, we clearly demonstrate that injection of
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miR-146a- and miR-155-containing exosomes results in delivery of
these miRNAs to a variety of mouse tissues, repression of target
genes and an altered inﬂammatory response in vivo, where miR-
155 promoted and miR-146a repressed inﬂammation in response
to endotoxin. This suggests that exosomal miR-146a could be used
as a prophylaxis or therapy to treat inﬂammatory diseases, such as
bacterial sepsis. Conversely, exosomal miR-155 could be used as an
adjuvant to improve vaccine efﬁcacy. However, it is also clear that
the full spectrum of applications whereby exosomal miRNAs can
be used is potentially quite broad and will require a great deal of
future work. As we reﬁne our understanding of how miRNAs are
loaded into exosomes and delivered in a functional manner to
speciﬁc recipient cells, such therapeutic approaches may become
feasible in the clinic.
Methods
Mice. miR-155 / (Allan Bradley Lab, Sanger Institute), miR-146a /
(David Baltimore Lab, California Institute of Technology), miR-155 and miR-146a
DKO (Ryan O’Connell, University of Utah), Wt (Jackson Labs) and CD45.1 Wt
(Jackson Labs) are on a C57BL6 genetic background and housed in the animal
facility at the University of Utah. Rab27 DKO (Rab27a ash/ash Rab27b / ) mice
(Tanya Tolmachova and Miguel C. Seabra, Imperial College London) were housed
at the Imperial College London under the UK Home Ofﬁce animal project license
70/7078 and the BM was sent to Utah for experiments together with the BM from
the Wt animals of similar age, sex and background (C57BL6). Experiments were
approved by the Institutional Animal Care and Use Committee at the University of
Utah. Mice were age matched and sex matched, and were in the age range of 8–16
weeks old. For BM reconstitutions, lethal irradiation (1,000 rads) was delivered
using an X-ray source. Following irradiation, mice were injected with three million
BM cells via retro-orbital injection. Escherichia coli LPS (Sigma) was administered
through i.p. injections at a sub-lethal concentration of 50 mg29. In other
experiments, exosomes were i.p. injected 24 h before LPS injection of the same
concentration.
Cells culture. BMDCs were derived from mouse BM by culturing red blood cell-
depleted BM in complete RPMI (10% fetal bovine serum, 100 units per ml peni-
cillin and 100 units per ml streptomycin, b-mercaptoethanol, glutamate, sodium
pyruvate, HEPES and non-essential amino acids) with 20 ngml 1 granulocyte
machrophage colony-stimulating factor for 3–4 days at 37 C with 5% CO2. The
cells were then cultured in 5ml complete RPMI with 20 ngml 1 granulocyte
machrophage colony-stimulating factor for an additional 3–4 days for a total of 7
days in culture. LPS stimulation was performed at a concentration of 500 ngml 1.
Cells were separated using a Transwell Permeable Support 0.4 mm Polycarbonate
Membrane 24mm insert six-well plates (Costar).
RNA sequencing. Wt exosomes were transferred to recipient miR-155 and miR-
146a DKO BMDCs. Three biological replicates from Wt donor and exosome-
recipient DKO BMDCs were submitted to the University of Utah’s High
Throughput Genomic Core for Illumina TrueSeq Small RNA Sample Prep. NTAs
were identiﬁed and frequencies of A, G, C and U additions were calculated as
described previously17 by our bioinformatics core facility. In addition, we analysed
each position in the mature miRNA sequences of miR-155 and miR-146a, and
calculated the percentage of observed bases at each position to determine any
changes in nucleotide composition between miRNAs in donor versus exosome-
recipient BMDCs. RNA sequencing data are deposited in GEO with the accession
number GSE67946.
Copy-number analysis. miRNA copy number was calculated in Wt and miR-
146a / donor cells, exosomes and miR-146a / BMDCs that received Wt
exosomes. Total RNA was isolated (using the miRNeasy kit) from one million
donor BMDCs and one million recipient BMDCs that were cultured with exosomes
from one million donor BMDCs collected after 24 h or exosomes isolated from one
million BMDCs after 24 h. Thirty nanograms of RNA isolated from these samples
was then used for qRT–PCR analysis. To make a standard curve, 1 ng of synthetic
single-stranded miR-146a (IDT custom RNA oligo—sequence: 50-UGAGAACUG
AAUUCCAUGGGUU-30) was spiked into either one million miR-146a /
BMDCs or exosomes isolated from one million miR-146a / BMDCs, and total
RNA was isolated in the same manner as our experimental samples (miRNeasy).
Thirty nanograms of this isolated RNA was used to preform a complementary
DNA reaction to use for standard curves. Standard curves for cells and exosomes
were made with these cDNA samples via serial dilutions and cp values were
determined via qPCR with miR-146a primers. The BMDC standard curve was then
used to determine copy number in our cellular samples and the BMDC exosome
standard curve was used to determine the copy number of miR-146a in our
exosome samples.
Mimic. miRNA mimics were purchased from Qiagen. Scrambled, seed mutant and
miR-mimic sequences are as follows:
miR-146a scramble (50-ACGAGUUACGUGGUACGUUAAU-30),
miR-146a seed mutant (50-UGUCAAGAGAAUUCCAUGGGUU-30),
miR-146a mimic (50-UGAGAACUGAAUUCCAUGGGUU-30),
miR-155 scramble (50-GGAUGUUAUUGCGUAUAUUAGGA-30),
miR-155 seed mutant (50-UUUGCUAAAAUUGUGAUAGGGGU-30) and
miR-155 mimic (50-UUAAUGCUAAUUGUGAUAGGGGU-30). Donor cells
were transfected with 30 ml of the hi-perfect transfection reagent (Qiagen) in 2ml
of serum-free media with 60 ng of each mimic. After 24 h, cells were washed three
times with PBS and given fresh medium. Exosomes were isolated 24 h after washing
and transferred to recipient cells for 24 h.
Luciferase reporter assay. Knockout BMDCs (2.5 105) were transfected with
30-UTR luciferase reporter constructs (for mir-155 / : pmiReport, Bach1, Bach1
155 mutant, 2mer29; (for miR-146 / : pmiReport, Traf6, Traf6 146a mutant45)
using Lonza’s Amaxa Mouse Dendritic Cell Nucleofector Kit, according to
manufacturer’s instructions. After 6 h of nucleofection, BMDCs were treated with
or without Wt BMDC-derived exosomes and luciferase activity was measured 24 h
later using a Dual Luciferase Kit (Promega). Luciferase repression of exosome-
treated BMDCs compared with no exosome treatment was calculated and graphed
as per cent change in luciferase activity. Renilla luciferase was used to normalize
ﬁreﬂy luciferase values. 2 mg of each construct was transfected into BMDCs.
Exosome isolation and procedures. For in-vitro experiments, we isolated
exosomes from approximately one million BMDCs cultured in media for 24 h and
transferred them to the same number of recipient BMDCs. Differential
centrifugation was performed to isolate exosomes from conditioned medium.
Initial spins consisted of a 10-min spin at 1,000g, a 2,000g spin for 10min and a
10,000g spin for 30min. The supernatant was retained each time. The supernatant
was then spun at 100,000g for 70min and the pellet was re-suspended in 1 PBS,
to dilute remaining soluble factors, followed by another centrifugation at 100,000g
for 70min. The ﬁnal pellet contained the exosomes, which were re-suspended
in tissue culture media. This protocol is based on previous exosome isolation
methods46. We used either a Beckman ultracentrifuge with a TI75 ﬁxed angle rotor
or a Thermo Scientiﬁc Sorvall Lynx 6000 with a T26-8 50 rotor. GW4869 is a
neutral sphingomyelinase 2 inhibitor that has been previously used to prevent
exosome release13,15. In some experiments, we treated BMDCs with 10 mM
GW4869 (Sigma-Aldrich) or vehicle for 24 h.
Exosome numbers for the miR-146a and miR-155 in-vivo experiments were
determined using the EXOCET Exosome Quantiﬁcation Assay Kit from System
Biosciences, according to kit instructions. Three plates of approximately three
million BMDCs each were cultured in media for 3 days. The supernatant from
these plates was collected and exosomes were isolated as described above.
Western blotting and enzyme-linked immunosorbent assay. Protein was
isolated with RIPA lysis buffer (RIPA buffer, phenylmethyl sulfonyl ﬂuoride, NaF,
NaVO4 and protease inhibitor). Total protein levels were quantiﬁed using a
Bio-Rad protein assay and equal amounts of protein were loaded and separated
using 12% (TRAF6, Ago2 and CD63) or 8% (SHIP1 and IRAK1) SDS–PAGE
followed by immunoblotting with appropriate antibodies. Antibodies include the
following: a-TRAF6 at 1:500 dilution (EP591Y Abcam, ab33915), a-b-actin anti-
body at 1:1,000 dilution (mAbcam 8226, ab8226), a-Ago2/eIF2C2 antibody at
1:200 dilution (Abcam, ab32381), a-CD63 (H-193) at 1:200 dilution (Santa Cruz
Biotechnology, sc-15363), a-SHIP1 (V-19) at 1:250 dilution (Santa Cruz Bio-
technology, sc-1963), and a-IRAK1 D5167 at 1:500 Dilution (Cell Signaling, 4504).
Western blottings were quantiﬁed using ImageJ software. The enzyme-linked
immunosorbent assay used to quantify mouse IL-6 and TNFa concentrations were
obtained from eBioscience and were performed using the manufacturer’s suggested
protocol. Images have been cropped for presentation. Full-size images are pre-
sented in Supplementary Figs 7–9.
RNA isolation and qRT–PCR. RNA isolation was performed using Qiagen’s
miRNeasy kit, according to manufacturer’s instructions. Mature miRNA cDNA
was made with a miRCURY LNA universal RT miRNA PCR kit using 10 ng of
RNA from each sample (Exiqon). qPCR of mature miRNA was performed with the
miRCURY LNA universal RT miRNA PCR kit SYBR green master mix (Exiqon)
with LNA primers for miR-146a-5p (Exiqon), mmu-miR155-5p (Exiqon), mmu-
miR-425-5p (Exiqon) and 5s rRNA (Exiqon). Custom LNA primers were also
made and designed by Exiqon to detect the miR-155 and miR-146a seed mutant
mimics (miR-146a design ID 410833-1) (miR-155 design ID 410829-1). 5s was
used to normalize expression. cDNA from total RNA was made with qScript using
30 ng of RNA from each sample (Quanta). qPCR was performed with Promega
GoTaq pPCR master mix. Primer sequences are as follows:
SHIP1-F (50-GAGCGGGATGAATCCAGTGG-30),
SHIP1-R (50-GGACCTCGGTTGGCAATGGTA-30),
BACH1-F (50-TGAGTGAGAGTGCGGTATTTGC-30),
BACH1-R (50-GTCAGTCTGGCCTACGATTCT-30),
HO1-F (50-TGACACCTGAGGTCAAGCAC-30),
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HO1-R (50-TCCTCTGTCAGCATCACCTG-30),
IRAK1-F (50-TGTGCCGCTTCTACAAAGTG-30),
IRAK1-R (50-TGTGAACGAGGTCAGCTACG-30),
TRAF6-F (50-AAGCCTGCATCATCAAATCC-30),
TRAF6-R (50-CTGGCACTTCTGGAAAGGAC-30).
L32-F (50-AGCTCCCAAAAATAGACGCAC-30) and
L32-R (50-TTCATAGCAGTAGGCACAAAGG-30). L32 levels were used to
normalize mRNA expression levels.
Electron microscopy. EM samples were prepared using differential centrifugation
from BMDC-conditioned media. Exosomal pellets were re-suspended in PBS and
processed by the University of Utah’s EM core facility for cryo-EM analysis.
Immunoprecipitations. An anti-pan Ago antibody (clone 2A8, Millipore) was was
used to IP Ago proteins. a-AGO and IgG control coated beads were prepared by
incubating magnetic protein G beads (Active motif) with each respective antibody
in IP lysis buffer (0.5% NP40, 150mM KCl, 1mM NaF, 25mM Tris, 2mM EDTA,
protease inhibitor and 0.5mM dithiothreitol) with rotation overnight at 4 C. One-
third of the protein lysate prepared from BMDCs that had received either Wt or
miR-155 / exosomes using IP lysis buffer was used for the IP. Bead–antibody
mixes were washed three times with lysis buffer with rotation at 4 C, re-suspended
in lysis buffer and added to the lysates. Lysates were incubated with bead–antibody
mix at 4 C with rotation overnight and then washed six times with IP wash buffer
(300mM NaCl, 50mM Tris,.01% NP40, 5mM MgCl2, 129ml dH2O), with the last
wash done using PBS. Protein was isolated from a fraction of the sample with
1 Laemmli diluted in lysis buffer and RNA was isolated from another fraction
using miRNeasy extraction. A western blotting for AGO2 (Abcam) and qRT–PCR
analysis for miR-155 and miR-146a were performed to conﬁrm AGO pulldown
and association with these miRNAs.
Flow cytometry. Fluorophore-conjugated monoclonal antibodies speciﬁc to
CD45.1, CD45.2, B220, CD3, CD11b or CD11c (Biolegend) were used to stain red
blood cell-depleted BM and spleen cells. These populations were sorted using a
FACS Aria II in the Flow Cytometry Core Facility at the University of Utah.
Statistics. Data were analysed using Student’s t-tests, to determine statistically
signiﬁcant differences between relevant samples. P-values were either listed or
represented by the following number of asterisks: *Po0.05; **Po0.01;
***Po0.001; ****Po0.0001.
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